Brainsway Ltd (BWAY NASDAQ) stock market data APIs
$15.1057
0.47(3.1%)
as of September 15, 2025
Try our APIs with
free plan!
Brainsway Ltd Financial Data Overview
Price chart is built with
Anychart
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Prev. Close
15.1057
Open
15.5772
High
15.5772
Low
14.9006
52 wk Range
7.84-16.25
Market Cap
298 M
P/E Ratio
55.9074
Shares Outstanding
18 913 K
Revenue
46 084 K
EPS
0.05
Beta
0.316
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Brainsway Ltd data using free add-ons & libraries
Get Brainsway Ltd Fundamental Data
Brainsway Ltd Fundamental data includes:
- Net Revenue: 46 084 K
- EBITDA: 3 321 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Brainsway Ltd News
New
Brainsway stock maintains Buy rating at H.C. Wainwright after strategic investments
Investing.com - H.C. Wainwright has reiterated a Buy rating and $17.00 price target on Brainsway (NASDAQ:BWAY), the $288 million market cap medical device company that has delivered an impressive 61% ...
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
BrainsWay Ltd. BWAY recently took a strategic step to expand its reach in the mental health market through a $5 million investment in Neurolief Ltd., a developer of wearable, non-invasive neuromodulat...
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device ...
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
